摘要
自身免疫性甲状腺病(AITD)是T淋巴细胞介导的器官特异性自身免疫病,协同刺激分子在AITD异常免疫反应的启动、维持和效应阶段均发挥重要作用。除了CD28/细胞毒性T淋巴细胞相关抗原(CTLA)-4-B7分子之外,CD40CD40配体、淋巴细胞功能相关抗原-1(LFA-1)-CD54、可诱导协同刺激分子(ICOS)-ICOS配体以及凋亡分子也参与了介导AITD的免疫功能紊乱。对协同刺激分子的深入研究,可以加深对AITD发生机制的认识,从而为临床提供新的免疫治疗途径。
出处
《国外医学（内分泌学分册）》
2005年第3期207-209,共3页
Foreign Medical Sciences(Section of Endocrinology)
基金
国家自然科学基金资助项目(30370678)
参考文献12
-
1McAdam AJ, Chug T, Lumelsky AE, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4^+ T-cells. J Immunol,2000,165:5035-5040.
-
2Kouki T, Sawai Y, Gardine CA, et al. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol,2000, 165:6606-6611.
-
3Tomer Y, Greenberg DA, Barbesino G, et al. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab, 2001,86:1687-1693.
-
4Haase C, Michelsen BK,Jorgensen TN. CD40 is necessary for activation of naive T cells by a dendritic cell line in vivo but not in vitro. Scand J Immunol, 2004,59: 237-245.
-
5Cron RQ. CD154 transcriptional regulation in primary human CD4 T cells. Immunol Res, 2003,27:185-202.
-
6Kim TY, Park YJ, Hwang JK, et al. A C/T polymorphism in the 5'-untranslated region of the CD40 gene is associated with Graves' disease in Koreans. Thyroid, 2003,13: 919-925.
-
7Arao T, Morimoto I, Kakinuma A, et al. Thyrocyte proliferation by cellular adhesion to infiltrating lymphocytes through the intercellular adhesion molecule-1/lymphocyte function-associated antigen-1 pathway in Graves' disease. J Clin Endocrinol Metab, 2000,85: 382-389.
-
8Jungheim K, Caspar G, Usadel KH, et al. Lymphocyte homing in xenotransplanted human thyroid tissue can be inhibited by LFA-1 and ICAM-1 antibodies. Thyroid,2004,14: 3-11.
-
9Dong C, Nurieva RI. Regulation of immune and autoimmume responses by ICOS. J Autoimmun, 2003,21: 255-260.
-
10Salmaso C, Bagnasco M, Pesce G, et al. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto' s thyroiditis and Graves' disease. Ann N Y Acad Sci,2002,66:496-501.
同被引文献8
-
1门敏,朱江,朱本章,王丽萍,马卫国,何岚,蒲丹,张进安.Graves病患者甲状腺组织中T细胞受体Vα基因限制性取用现象的研究[J].中华内分泌代谢杂志,2007,23(3):254-255. 被引量：1
-
2Cabrian KM, Berry KK, Shuford WW, et al. Suppression of Tcell-dependent immune responses in monkeys by CTLA-4Ig [J]. Transplant Proc, 1996, 28(6) :3261-3262.
-
3Martin A, Matsuoka N, Zhang J, et al. Preservation of function human thyroid “organoid” in the scid mouse. IV. In vivo selection of an intrathyroidal T cell receptor repertoire [J]. Endocrinology, 1997, 138(11):4868-4869.
-
4Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7 [J]. J Exp Med, 1991, 174(3) :561-569.
-
5Kouki T, Sawai Y, Gardine CA, et al. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease [J]. J Immunol, 2000, 165:6606-6611.
-
6Duby AD, Seidman JG. Abnormal recombination products results from aberrant DNA rearrangement of the human T-cell antigen receptor chain gene [J]. Proc Natl Acad Sci USA, 1986, 83: 4890-4894.
-
7Sato N, Nakayama M, Arai K, et al. Fluctuation of chromatin unfolding associated with variation in the level of gene expression [J]. Gene Cells, 2004, 9(7):619-630.
-
8张进安,王一理,雒文田,施秉银,朱本章,司履生.T细胞受体Vβ基因在自身免疫性甲状腺病病变组织中的表达及意义[J].中华病理学杂志,2001,30(4):268-272. 被引量：4
-
1梁军,邹彩艳,赵家军.HLA、CTLA-4、PTPN22基因在自身免疫性甲状腺病遗传易感性中的作用[J].新医学,2009,40(3):194-195. 被引量：1
-
2陈维.不同剂量缬沙坦对冠状动脉介入术后患者血清中PPARγ含量及机体炎症程度的影响[J].海南医学院学报,2016,22(20):2401-2404. 被引量：6
-
3结缔组织疾病[J].中国医学文摘（皮肤科学）,2009,0(4):245-248.
-
4吴雪梅,武革（审校）.协同刺激分子在Graves病发病机制中的研究进展[J].国际免疫学杂志,2007,30(3):160-163.
-
5王菁.CD40-CD40L的功能及与疾病的关系[J].国外医学（儿科学分册）,1998,25(5):238-241. 被引量：2
-
6赵素贤,赵景民.儿童自身免疫性肝炎的特点及研究进展[J].国际消化病杂志,2007,27(1):30-32. 被引量：3
-
7王萍萍,蒋玲.Graves病的遗传及易感性[J].山东医药,2005,45(7):62-63. 被引量：1
-
8孙兵.Th1细胞是诱导器官特异性自身免疫病的主要原因[J].上海免疫学杂志,1999,19(6):323-325.
-
9赵建宏.系统性红斑狼疮遗传易感性研究进展[J].济宁医学院学报,2003,26(1):67-69.
-
10陈健.结缔组织病与脑血管病[J].山东医药,2008,48(23):108-109. 被引量：2
